To overcome the many challenges posed by the use of viral vectors (High development and manufacturing costs, production scale up complexity, immunogenicity and genotoxicity risks...), we are developing a unique DNA vector to reduce the cost and improve efficiency of gene therapy. Indeed, Fabmid develops a DNA vector both easy to produce and with all the properties required from a good vector: high cell transfection efficiency, low toxicity, high stability and selectivity.